News

One size does not fit all when it comes to cystic fibrosis patients’ symptoms, despite the commonality of a mutated gene. Some patients endure severe life-long airway infections while others are relatively unaffected by their condition. Michael Knowles, MD, professor of pulmonary and critical care medicine at the University…

N30 Pharmaceuticals, Inc., a clinical-stage pharmaceutical firm committed to developing product candidates to address cystic fibrosis (CF), recently announced that the company has changed its name to Nivalis Therapeutics, Inc. Nivalis Therapeutics’ lead product candidate is N91115, a new inhibitor of S-nitrosoglutathione reductase (GSNOR) for the treatment of CF. The company’s new name, Nivalis…

An article published in the Journal of Clinical Investigation provides evidence that challenges the previously held assumptions as to where the abnormal accumulation of sticky mucus, a key feature in cystic fibrosis (CF), originates. The study entitled “Defective goblet cell exocytosis contributes to murine cystic…

Although I am a student in a biomedical science program I have only begun in the past two years to educate myself in issues relating to Cystic Fibrosis. When I was growing up I tried to hide from any literature relating to CF in hopes that the disease would feel…

Garlic may help improve the symptoms of cystic fibrosis (CF) due to the presence of a chemical called allicin, which has been shown to kill opportunistic bacteria that are likely to cause lung infections in the thick, built up mucus of CF patients. The discovery that allicin may…

Drug discovery company Enterprise Therapeutics Ltd. has successfully raised $2.4 million through a Series-A financing round. The company, based at the University of Sussex in the United Kingdom, is focused on creating novel therapies for respiratory diseases, such as cystic fibrosis (CF). A portion the funding will be invested in the…